Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
about
First line vs delayed transplantation in myeloma: Certainties and controversiesMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementLenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialPractical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial.Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.Lenalidomide in multiple myeloma: current experimental and clinical data.Immunomodulatory drugs in multiple myeloma.Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaInduction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma.Lenalidomide in the treatment of young patients with multiple myeloma: from induction to consolidation/maintenance therapyHematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.Thalidomide and its analogues in the treatment of Multiple MyelomaMyeloma today: Disease definitions and treatment advances.Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyThe role of Dickkopf-1 in bone development, homeostasis, and diseaseTreatment of plasma cell dyscrasias with lenalidomide.Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplants.Lenalidomide and its role in the management of multiple myeloma.The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma.Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myelomaImproving stem cell mobilization strategies: future directions.Initial therapy in multiple myeloma: investigating the new treatment paradigm.Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesFront-line treatment in younger patients with multiple myeloma.
P2860
Q26745957-04513DA8-3C95-40A4-9930-0DC368336A59Q26998884-F7F452AD-99EC-45C3-92E6-59746618CB57Q30433139-86166AD0-8FD3-497A-9A2B-87CB4EF7FA84Q33404007-DDC3BBE1-8E3E-4E26-89D3-0FDADEA4BC78Q33411277-32DF2D02-8011-47AC-BB21-42D823A5E743Q33543723-2E635E13-8745-4180-BA2B-5D09BFBC5A00Q33573756-DED9627F-09CB-48D6-B137-B52099C3559CQ33973877-45341D0D-A940-46A2-B2C4-BF52C450BA45Q34038564-A9AF9C34-C614-4C28-BDE9-CA232CB186B3Q34074803-5D6E5C2B-9AFF-440C-AB1F-AA47BFB6895BQ34325722-44D588ED-1D11-4565-89E9-E408901C4D69Q34490998-6813CFEF-B087-4CD1-80D1-5A9D4E6599ADQ34604658-08B3E45C-5493-42FF-9AE2-EF8F8A5798C9Q34775475-D0513E3D-91F6-45D6-B719-A3EFB14B228CQ35157385-A555746F-C1D1-41A9-BEBC-84DB2274937CQ35685454-57D16821-E9FC-480A-94B6-F6ABE5F38D17Q35911212-22D55862-C143-4FBB-9E91-20AED0369140Q35994520-052E0342-0C0F-4547-B1DB-1F47322EBF8CQ36012111-2918C246-4D04-48AF-891D-0BAB1CF65A3FQ36014687-E82B7498-335C-493A-88EB-529EC05DAB88Q36104325-CF2AE7F1-3BE5-440D-A6EA-A49D2C64F58AQ36428104-45370725-69A2-4EF9-8223-8B5A635B190FQ36444523-A1EC05DE-0222-4C7E-9BC7-DE617A96D243Q36470699-3DB233D7-66E1-4621-9E7B-3B21E28AC21DQ36570256-C475E7A1-D04B-47D8-AA9C-3444B8FEAE9DQ36765107-716F5436-07DB-4D7C-8CF9-4CA0E0F26A1DQ36777233-A2CCE59E-56C9-47A6-9D0A-6DBA4218899DQ36794316-32C1A1B4-5D23-41A0-87AB-D80FE8925AFCQ36963203-5B4E93B9-6027-4725-B74B-7ABDF6C2029AQ37066218-2465A641-E298-46C2-9335-38156420517FQ37176044-56228F7F-98B6-4C40-A5AE-A8891930673BQ37181947-4E767145-F836-46DF-BAFD-7A9F815FF5BEQ37183439-2C9F2A93-D94E-4DA9-AD0E-9EB011D2690EQ37209935-70746ED0-8BD1-488D-BAAB-569C3760FE18Q37335216-D1C3981F-EA14-4F26-8EF3-A3447812E132Q37367235-10181794-C820-4358-85EA-79629041A721Q37411805-5602A27B-D8DD-4859-93DF-015B86BD1FFEQ37429248-8F0FF67D-F8BF-471B-BD94-D2BDB8051224Q37454445-77271831-2C67-474A-95BD-D902F4515B10Q37457273-D993B6C2-CA1F-43DB-8CBC-87A55A3CA11C
P2860
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Impact of lenalidomide therapy ...... with newly diagnosed myeloma.
@en
type
label
Impact of lenalidomide therapy ...... with newly diagnosed myeloma.
@en
prefLabel
Impact of lenalidomide therapy ...... with newly diagnosed myeloma.
@en
P2093
P2860
P356
P1433
P1476
Impact of lenalidomide therapy ...... with newly diagnosed myeloma.
@en
P2093
Gastineau DA
Rajkumar SV
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404801
P577
2007-06-21T00:00:00Z
P5875
P6179
1011029060